<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584791</url>
  </required_header>
  <id_info>
    <org_study_id>KOPIDO STENT</org_study_id>
    <nct_id>NCT01584791</nct_id>
  </id_info>
  <brief_title>Korean Multicenter Randomized Controlled Trial (RCT) of Pidogul for Patients With Coronary Stenting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanmi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The aim of the current study is to compare the antiplatelet efficacy and safety of
      clopidogrel napadisilate and clopidogrel bisulfate in Coronary Artery Disease (CAD) patients
      after coronary stent implantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of P2Y12 receptor inhibition</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events after study medication</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>clopidogrel napadisilate + aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel bisulfate + aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel napadisilate + aspirin</intervention_name>
    <description>clopidogrel napadisilate 75mg + aspirin 100mg</description>
    <arm_group_label>clopidogrel napadisilate + aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel bisulfate + aspirin</intervention_name>
    <description>clopidogrel bisulfate 75mg + aspirin 100mg</description>
    <arm_group_label>clopidogrel bisulfate + aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Korean men and women between the age of 20 and 85

          -  Patients who were diagnosed as having CAD

          -  Patients who were planned to undergo PCI

        Exclusion Criteria:

          -  Patients who were not treated with PCI or intended to treat with PCI but failed

          -  Patients who were were taking or had taken other antiplatelet or anticoagulant for
             more than 2 weeks within the prior 30 days

          -  Patients who were had a history of alcohol abuse or intoxication; (4) had
             hypersensitivity to clopidogrel or aspirin

          -  Patients who were had hypersensitivity to clopidogrel or aspirin

          -  Patients who were had abnormal laboratory results indicative of liver disease

          -  Patients who were had blood coagulation disorders, uncontrolled severe hypertension,
             active bleeding, or history of severe bleeding, such as intracranial hemorrhage or
             ulcer bleeding

          -  Patients who were were pregnant, breastfeeding, or not using effective methods of
             contraception

          -  Patients who were had other contraindication to study drug

          -  Patients who were had participated in another clinical study within 4 weeks prior to
             the start of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyo-Soo Kim</investigator_full_name>
    <investigator_title>Professor, Department of Internal Medicine, Seoul National University Hospital</investigator_title>
  </responsible_party>
  <keyword>CAD</keyword>
  <keyword>PCI</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

